We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Approach to Aid in Diagnosing Lower Back Pain Revealed

By LabMedica International staff writers
Posted on 27 Jan 2016
In a clinical study, scientists have identified a potential new method, based on biochemical profiling of serum for circulating cytokines, that may assist in refining personalized diagnoses of disc diseases and possibly even in distinguishing between severe and mild conditions.

Physicians trying to diagnose low-back pain (LBP) look at many potential causes and unpredictable responses to treatment as LBP can come from any of various causes that can present in similar ways. In a new study, scientists from Feinstein Institute for Medical Research (Manhasset, NY, USA) in collaboration with clinicians from Northwell Health (Manhasset, NY, USA) performed multiplex assays on blood serum samples from 133 participants to examine biochemical profiles of cytokines (and matrix metalloproteinases).

Image: T1 weighted sagittal cervical spine MRI showing degenerative disc disease, osteophytes, and osteoarthritis of C5-C6 (Image courtesy of Wikimedia).
Image: T1 weighted sagittal cervical spine MRI showing degenerative disc disease, osteophytes, and osteoarthritis of C5-C6 (Image courtesy of Wikimedia).

The team, led by Nadeen Chahine, PhD, associate investigator, Feinstein Institute, recruited participants from Northwell Health: from a spine neurosurgery practice (n = 80), a back pain management practice (n = 27), a control cohort (n = 26). Participants with LBP had been diagnosed with intervertebral disc herniation (IDH), spinal stenosis (SS), or degenerative disc disease (DDD), but had not yet begun treatment. The main findings were that serum levels of the proinflammatory cytokine interleukin-6 (IL-6) were significantly higher in subjects with LBP compared with control participants, and that participants with SS or DDD had higher levels than those with IDH and controls. Further analysis showed positive correlations between IL-6 levels and BMI, symptom duration, and age.

The team’s findings suggest that patients with LBP have low-grade systemic inflammation and that profiling of circulating cytokines can assist in improving diagnosis of LBP.

"We're very excited by the results of this clinical study and will continue to study cytokine levels in the future," said Dr. Chahine.

The study, by Weber KT et al., was published January 7, 2016, in the journal Arthritis Research and Therapy.

Related Links:

Feinstein Institute for Medical Research
Northwell Health



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Manual Pipetting Aid
Pipette Controllers macro

Latest Immunology News

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
27 Jan 2016  |   Immunology

Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
27 Jan 2016  |   Immunology

Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
27 Jan 2016  |   Immunology



INTEGRA BIOSCIENCES AG